仟源医药(300254) - 2015年7月20日投资者关系活动记录表

Group 1: Company Operations - The company operates in gene preservation and prenatal environment testing through self-operated and agency models, with a team of approximately 50 people established for sample hospitals across multiple provinces [2] - The company aims to exceed 500 hospitals covered by signed distributors nationwide this year, having already surpassed 200 [3] - The current price for gene preservation is 4,960 yuan per case, with a high gross profit margin [3] Group 2: Investment and Partnerships - The company has invested in a new drug research and development company and is preparing to discuss another investment in a small RNA innovative drug company [4] - The company has not yet engaged with state-owned pharmaceutical enterprises regarding reform [4] - The acquisition of Sichuan Guanghan Traditional Chinese Medicine Co., Ltd. was driven by the potential for development in the traditional Chinese medicine sector and the opportunity to create products related to maternal and infant health [4] Group 3: Financial Activities - The funds for the non-public issuance of shares are in place, pending approval from the China Securities Regulatory Commission for the issuance plan [3]